Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene (original) (raw)

• Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ . Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
  Article PubMed Google Scholar
• Alberts DS, Delforge A . Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life. Semin Oncol 2006; 33 (6 Suppl 12): S8–S17.
  Article PubMed Google Scholar
• Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D . Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 437–443.
  Article CAS PubMed Google Scholar
• Kanerva A, Raki M, Hemminki A . Gene therapy of gynaecological diseases. Expert Opin Biol Ther 2007; 7: 1347–1361.
  Article CAS PubMed Google Scholar
• Davis JJ, Fang B . Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 2005; 7: 1380–1389.
  Article CAS PubMed Google Scholar
• Parato KA, Senger D, Forsyth PA, Bell JC . Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965–976.
  Article CAS PubMed Google Scholar
• Schepelmann S, Springer CJ . Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 2006; 6: 647–670.
  Article CAS PubMed Google Scholar
• Liu TC, Galanis E, Kirn D . Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101–117.
  Article CAS PubMed Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.
  Article CAS PubMed Google Scholar
• Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 2004; 23: 1666–1670.
  PubMed Google Scholar
• Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636–642.
  Article CAS PubMed Google Scholar
• Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL . Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000; 6: 3342–3353.
  CAS PubMed Google Scholar
• Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266–1270.
  CAS PubMed Google Scholar
• Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ . Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656–4662.
  CAS PubMed Google Scholar
• Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW . Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696–1701.
  CAS PubMed Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263–275.
  Article CAS PubMed Google Scholar
• Tseng JC, Hurtado A, Yee H, Levin B, Boivin C, Benet M et al. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 2004; 64: 6684–6692.
  Article CAS PubMed Google Scholar
• Zeh HJ, Bartlett DL . Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002; 9: 1001–1012.
  Article CAS PubMed Google Scholar
• Guo ZS, Bartlett DL . Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 2004; 4: 901–917.
  Article CAS PubMed Google Scholar
• Shen Y, Nemunaitis J . Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 2005; 11: 180–195.
  Article CAS PubMed Google Scholar
• Thorne SH, Bartlett DL, Kirn DH . The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther 2005; 5: 429–443.
  Article CAS PubMed Google Scholar
• Karupiah G, Coupar B, Ramshaw I, Boyle D, Blanden R, Andrew M . Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol Cell Biol 1990; 68: 325–333.
  Article CAS PubMed Google Scholar
• Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7: 66–73.
  Article CAS PubMed Google Scholar
• McCart JA, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 2004; 10: 553–561.
  Article CAS PubMed Google Scholar
• McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751–8757.
  CAS PubMed Google Scholar
• Guo ZS, Naik A, O’Malley ME, Popovic P, DeMarco R, Hu Y et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and anti-apoptosis genes SPI-1 and SPI-2. Cancer Res 2005; 65: 9991–9998.
  Article CAS PubMed Google Scholar
• Yang ST, Guo ZS, O’Malley ME, Yin XY, Zeh HJ, Bartlett DL . A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Ther 2007; 14: 638–647.
  Article PubMed Google Scholar
• Naik AM, Chalikonda S, McCart JA, Xu H, Guo ZS, Langham G et al. Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther 2006; 17: 31–45.
  Article CAS PubMed Google Scholar
• Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409–422.
  Article CAS PubMed Google Scholar
• Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ . The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8: S68–S73.
  Article CAS PubMed Google Scholar
• Niculescu-Duvaz I, Springer CJ . Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30: 71–88.
  Article CAS PubMed Google Scholar
• Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A . Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002; 62: 6089–6098.
  CAS PubMed Google Scholar
• Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I et al. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res 2007; 67: 4949–4955.
  Article CAS PubMed Google Scholar
• Gnant M, Puhlmann M, Alexander HR, Bartlett DL . Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-flurocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999; 59: 3396–3403.
  CAS PubMed Google Scholar
• Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL . Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999; 10: 649–657.
  Article CAS PubMed Google Scholar
• McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000; 7: 1217–1223.
  Article CAS PubMed Google Scholar
• Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59: 1417–1421.
  CAS PubMed Google Scholar
• Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21: 585–591.
  Article CAS PubMed Google Scholar
• Erbs P, Exinger F, Jund R . Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans. Curr Genet 1997; 31: 1–6.
  Article CAS PubMed Google Scholar
• Chakrabarti S, Sisler JR, Moss B . Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 1997; 23: 1094–1097.
  Article CAS PubMed Google Scholar
• Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG . In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055–1063.
  Article CAS PubMed Google Scholar
• Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274–5283.
  CAS PubMed Google Scholar
• Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM . In vivo analysis of the ‘bystander effect’: a cytokine cascade. Exp Hematol 1996; 24: 829–838.
  CAS PubMed Google Scholar
• Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK et al. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 2005; 9: 1068–1077; discussion 1077–1079.
  Article PubMed PubMed Central Google Scholar
• Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther 2007; 14: 20–29.
  Article CAS PubMed Google Scholar